What challenge is ROADMAP facing?

In the context of demographic change, Europe is facing an acute healthcare challenge. In no area is this more apparent than in Alzheimer’s disease (AD) and dementia. AD and related dementias affect nearly 50 million individuals worldwide with prevalence projected to double over the next twenty years.

So far there is no cure for AD and challenges in the evaluation of early disease interventions within the current assessment systems have not changed. Consequently, the precision medicine approach to health funding requires new models that encompass all the available evidence for the identification of best suited treatments for different groups within the AD continuum.


Read more about the state of precision medicine in AD